HOME  | CONTACT  | PATIENT LOGIN  | CLINIC LOGIN  | FAQ
  • PATIENTS &
    HEALTHY VOLUNTEERS
  • INVESTIGATORS
  • CROS / SPONSORS
  • CAREERS
  • TRIAL ALERTS

TRIALS SEARCH
      
  • HEALTH NEWS

  • RSS FEEDS

  • ABOUT TRIALS

  • LINK TO US


View Clinical Trial (Medical Research Study)


A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b HCV In

Signup
Browse Studies

City:   Newport News
State:   Virginia
Zip Code:   23602
Conditions:   Chronic Genotype 1a or 1b HCV Infection
Purpose:   This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection.
Study Summary:  
Criteria:   Inclusion Criteria: - Adult subjects 18 and older with chronic HCV infection - Liver biopsy results (performed no more than 3 years prior to Screening) indicating the absence of cirrhosis - Monoinfection with HCV genotype 1a or 1b - Interferon ineligible or intolerant - Body mass index (BMI) between 18 and 40 kg/m2 - Use of highly effective contraception methods if female of childbearing potential or sexually active male - Screening laboratory values within defined thresholds - Has not been exposed to any investigational drug or device within 30 days of the Screening visit - Able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments Exclusion Criteria: - Prior treatment of HCV with any direct-acting antiviral (whether approved or experimental) - Decompensated liver disease or cirrhosis - Co-infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype - History of difficulty with blood collection and/or poor venous access - Pregnant or nursing female or male with pregnant female partner - Chronic liver disease of a non-HCV etiology - Suspicion of hepatocellular carcinoma - Clinically-relevant drug abuse
NCT ID:   NCT01434498
Primary Contact:   Study Director
John McNally, PhD
Gilead Sciences

Raquel Garlick
Email: Raquel.Garlick@gilead.com
Backup Contact:   N/A
Location Contact:   Newport News, Virginia 23602
United States



There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:   ClinicalTrials.gov
Date Processed:   May 19, 2013
Modifications to this listing:   Only selected fields are shown, please use the link below to view all information about this clinical trial.
Click to view Full Listing


If you would like to be contacted by the clinical trial representative please enter your contact information, then click "I Am Interested In This Study"
First Name:  
Last Name:  
Email Address:  
Confirm Email:    
Daytime Phone (eg. 555-555-5555):  
City:  
State:
Zip Code:    
Best Time to Call:  
Questions/Comments:  
  • NEARBY STUDIES

 
Clinical Connections Home | Investigators | CROs / Sponsors | Clinical Trials Notification | Search Clinical Trials | About Clinical Trials | Links | Terms And Conditions | Sitemap | Suggestions / Feedback
© 1998-2013 | All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted worldwide.

ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.